Important Matters:

Manulife Financial-S (00945) has reached a reinsurance agreement worth 5.4 billion Canadian dollars with RGA.

Sihuan Pharm (00460): Huisheng Biotechnology and Miyandy Space have reached an exclusive authorization cooperation on the use of Somatostatin analog injection for weight loss.

Sino Biopharm (01177): A new indication for the first-line treatment of advanced hepatocellular carcinoma with Anlotinib Hydrochloride Capsules combined with Pembrolizumab Injection has obtained acceptance for market application.

chinares pharma (03320): china resources sanjiu medical & pharmaceutical (000999.SZ) will sell 51% of its stake in Kunshan Pharmaceutical (600422.SH).

[Financial Data]:

In the third quarter, the net income attributable to Baidu was 7.632 billion yuan, an increase of 14% year-on-year and 39% quarter-on-quarter.

Yidu Technology (02158) announced its interim results with a gross profit of 0.117 billion yuan, continuing to maintain its position as the number one brand in hospital clinical research.

KE Holdings-W (02423) released its third-quarter performance, with a net revenue of 22.6 billion yuan and a gross margin of 22.7%.

Baozun-W (09991) had a total net revenue of 2.057 billion yuan in the third quarter, a year-on-year increase of 12.8%.

[Stock Repurchase]:

Tencent Holdings (00700) spent 0.704 billion Hong Kong dollars on November 21 to repurchase 1.72 million shares.

Kuaishou-W (01024) spent 0.162 billion Hong Kong dollars on November 21 to repurchase 3.452 million shares.

Alibaba-W (09988) spent 39.9934 million US dollars on November 20 to repurchase 3.68 million shares.

For more details, please refer to the CITIC Securities website ().